Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 16/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29763302 | 0.88 | ABCG2 (0.64) | ABCG2MEN1MAPTKMT2AGAA | |
| SCHEMBL1592526 | 0.88 | ABCG2 (0.64) | ABCG2MEN1MAPTKMT2AGAA | |
| SCHEMBL1592610 | 0.88 | ABCG2 (0.63) | ABCG2MEN1MAPTKMT2AGAA | |
| SCHEMBL1593390 | 0.88 | ABCG2 (0.63) | ABCG2MEN1MAPTKMT2AGAA | |
| SCHEMBL27907052 | 0.84 | ABCG2 (0.62) | ABCG2MEN1MAPTKMT2AGAA | |
| SCHEMBL1594413 | 0.83 | ADORA2A (0.57) | ABCG2MEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL1592702 | 0.81 | ABCG2 (0.57) | ABCG2MAPTSMN1; SMN2ADORA2AABCB1 | |
| SCHEMBL27815788 | 0.81 | ABCG2 (0.64) | ABCG2MEN1MAPTKMT2AGAA | |
| SCHEMBL5031319 | 0.80 | NFKB1 (0.56) | ABCG2MEN1MAPTKMT2AGAA | |
| SCHEMBL1592596 | 0.78 | ABCG2 (0.56) | ABCG2MEN1MAPTKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092490-A1 | PYRIMIDINES, TRIAZINES AND THEIR USE AS PHARMACEUTICAL AGENTS | THE UNIVERSITY OF NOTTINGHAM (GB) | 2011-04-21 | — | — | US | disclosed |
| WO-2009118567-A2 | PYRIMIDINES, TRIAZINES AND THEIR USE AS PHARMACEUTICAL AGENTS | THE UNIVERSITY OF NOTTINGHAM (GB) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092490-A1 | PYRIMIDINES, TRIAZINES AND THEIR USE AS PHARMACEUTICAL AGENTS | HRH2, HRH3, HRH4 | ABCG2 41/4885MEN1 3293/4885MAPT 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.